Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Aytu Biopharma (AYTU) over the last 9 years, with Q4 2025 value amounting to $2.9 million.

  • Aytu Biopharma's Other Accumulated Expenses fell 5887.73% to $2.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.9 million, marking a year-over-year decrease of 5887.73%. This contributed to the annual value of $3.4 million for FY2025, which is 6229.64% down from last year.
  • Latest data reveals that Aytu Biopharma reported Other Accumulated Expenses of $2.9 million as of Q4 2025, which was down 5887.73% from $2.0 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Other Accumulated Expenses ranged from a high of $9.2 million in Q4 2023 and a low of $2.0 million during Q3 2025
  • In the last 5 years, Aytu Biopharma's Other Accumulated Expenses had a median value of $7.1 million in 2023 and averaged $6.1 million.
  • In the last 5 years, Aytu Biopharma's Other Accumulated Expenses soared by 61936.94% in 2021 and then plummeted by 7506.65% in 2025.
  • Over the past 5 years, Aytu Biopharma's Other Accumulated Expenses (Quarter) stood at $3.2 million in 2021, then soared by 146.86% to $7.8 million in 2022, then rose by 17.91% to $9.2 million in 2023, then dropped by 23.04% to $7.1 million in 2024, then tumbled by 58.88% to $2.9 million in 2025.
  • Its Other Accumulated Expenses was $2.9 million in Q4 2025, compared to $2.0 million in Q3 2025 and $3.4 million in Q2 2025.